Literature DB >> 23063678

Degree of damage to the small bowel and serum antibody titers correlate with clinical presentation of patients with celiac disease.

Juha Taavela1, Kalle Kurppa, Pekka Collin, Marja-Leena Lähdeaho, Teea Salmi, Päivi Saavalainen, Katri Haimila, Heini Huhtala, Kaija Laurila, Harri Sievänen, Markku Mäki, Katri Kaukinen.   

Abstract

BACKGROUND & AIMS: In patients with celiac disease, gluten-induced lesions of the small-bowel mucosa develop gradually. However, it is not clear whether clinical presentation correlates with the degree of mucosal damage based on histology analysis. We investigated whether the degree of mucosal damage to the small bowel correlates with clinical presentation and serum markers of celiac disease.
METHODS: We collected results from serology tests and mucosal biopsy samples from 638 consecutive patients with celiac disease and compared them with reported gastrointestinal symptoms, health-related quality-of-life scores, results from laboratory tests, and bone mineral densities of patients. We assessed mucosal injury based on the ratio of villous height to crypt depth, numbers of intraepithelial CD3(+) cells, and semiquantitative Marsh classification criteria. Correlations were established based on the Pearson or Spearman coefficients.
RESULTS: The ratio of the villous height to crypt depth correlated with the severity of gastrointestinal symptoms, quality-of-life scores, laboratory test results, numbers of intraepithelial CD3(+) cells, and serum levels of antibodies associated with celiac disease. There was no correlation between the ratio of villous height to crypt depth and bone mineral density. The number of intraepithelial CD3(+) cells was not associated with symptoms, whereas the Marsh classification and serum levels of antibodies associated with celiac disease correlated with gastrointestinal symptoms, laboratory test results, and numbers of intraepithelial CD3(+) cells.
CONCLUSIONS: The ratio of small-bowel villous height to crypt depth and results from serology tests correlate with reported symptoms and quality of life of patients with celiac disease. Patient-reported outcomes are therefore of value, in addition to histology findings, in assessing patients with celiac disease.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23063678     DOI: 10.1016/j.cgh.2012.09.030

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  23 in total

1.  Predictors and Significance of Incomplete Mucosal Recovery in Celiac Disease After 1 Year on a Gluten-Free Diet.

Authors:  Henna Pekki; Kalle Kurppa; Markku Mäki; Heini Huhtala; Harri Sievänen; Kaija Laurila; Pekka Collin; Katri Kaukinen
Journal:  Am J Gastroenterol       Date:  2015-06-02       Impact factor: 10.864

Review 2.  (Outcome) Measure for (Intervention) Measures: A Guide to Choosing the Appropriate Noninvasive Clinical Outcome Measure for Intervention Studies in Celiac Disease.

Authors:  Prashant Singh; Jocelyn A Silvester; Daniel Leffler
Journal:  Gastroenterol Clin North Am       Date:  2018-12-13       Impact factor: 3.806

Review 3.  Anti-type 2 transglutaminase antibodies as modulators of type 2 transglutaminase functions: a possible pathological role in celiac disease.

Authors:  Stefania Martucciello; Gaetana Paolella; Carla Esposito; Marilena Lepretti; Ivana Caputo
Journal:  Cell Mol Life Sci       Date:  2018-08-22       Impact factor: 9.261

4.  Identification of a serum transglutaminase threshold value for the noninvasive diagnosis of symptomatic adult celiac disease patients: a retrospective study.

Authors:  Marco Di Tola; Mariacatia Marino; Simone Goetze; Rossella Casale; Sara Di Nardi; Raffaele Borghini; Giuseppe Donato; Antonio Tiberti; Antonio Picarelli
Journal:  J Gastroenterol       Date:  2016-02-29       Impact factor: 7.527

5.  Thyroid-associated orbitopathy is linked to gastrointestinal autoimmunity.

Authors:  K A Ponto; D Schuppan; I Zwiener; H Binder; A Mirshahi; T Diana; S Pitz; N Pfeiffer; G J Kahaly
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

Review 6.  [Histological diagnosis and complications of celiac disease. Update according to the new S2k guidelines].

Authors:  D E Aust; H Bläker
Journal:  Pathologe       Date:  2015-03       Impact factor: 1.011

7.  Children with celiac disease and high tTGA are genetically and phenotypically different.

Authors:  Amani Mubarak; Eric Spierings; Victorien M Wolters; Henny G Otten; Fiebo J W ten Kate; Roderick H J Houwen
Journal:  World J Gastroenterol       Date:  2013-11-07       Impact factor: 5.742

8.  Clinical features of celiac disease: a prospective birth cohort.

Authors:  Daniel Agardh; Hye-Seung Lee; Kalle Kurppa; Ville Simell; Carin Andrén Aronsson; Ola Jörneus; Michael Hummel; Edwin Liu; Sibylle Koletzko
Journal:  Pediatrics       Date:  2015-03-02       Impact factor: 9.703

9.  Anaemia in Dermatitis Herpetiformis: Prevalence and Associated Factors at Diagnosis and One-year Follow-up.

Authors:  Anna Alakoski; Camilla Pasternack; Timo Reunala; Katri Kaukinen; Heini Huhtala; Eriika Mansikka; Juha Jernman; Kaisa Hervonen; Teea Salmi
Journal:  Acta Derm Venereol       Date:  2021-04-29       Impact factor: 3.875

Review 10.  Transglutaminase 2 and Transglutaminase 2 Autoantibodies in Celiac Disease: a Review.

Authors:  Tiina Rauhavirta; Minna Hietikko; Teea Salmi; Katri Lindfors
Journal:  Clin Rev Allergy Immunol       Date:  2019-08       Impact factor: 10.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.